Search Browse Earnings

Vistagen Therapeutics, Inc.

Nasdaq:VTGN

Pharmaceutical Preparations·SOUTH SAN FRANCISCO, CA

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

Vistagen Therapeutics, Inc. — SlamSEC

Revenue

$354,000

+0.0% YoY

FY 2023

Adj. EBITDA

-$32.9M

-9292.1% margin

FY 2025

Net Income

-$29.4M

-8294.4% margin

FY 2025

EPS (Diluted)

-$1.52

FY 2025

Stock Price

$0.61

+1.8%

2026-03-09

52W Range

$0.43 – $5.14

P/E Ratio

-0.4x

Market Cap

$24.2M

Cash

$119.2M

FY 2025

Total Debt

$1.6M

FY 2016

Net Cash

$117.6M

FY 2016

Enterprise Value

-$93.3M

Debt / EBITDA

3.6x

FY 2023

EV / EBITDA

2.8x

Employees

—